-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Intellia Therapeutics, Lowers Price Target to $45

Benzinga·05/12/2025 13:24:09
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $55 to $45.